Molecular biology

Global Gene Therapy Market Projected to Grow with a CAGR of 34.8% During the Forecast Period, 2019-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 25, 2020
Health, Genetics, Branches of biology, Articles, Biology, Molecular biology, Emerging technologies, Biotechnology, Medical genetics, Bioethics, Gene therapy, Therapy

The "Gene Therapy Market by Vector Type, Gene Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Therapy Market by Vector Type, Gene Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
  • In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.
  • However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market.
  • Oncological disorders segment generated the highest revenue, and is expected to continue its dominance in future in the global gene therapy market.

Twist Bioscience and Miroculus Agree to Collaborate on Next-Generation Sequencing Target Enrichment and Library Preparation Tools for Clinical Research

Retrieved on: 
Tuesday, February 25, 2020
Science, Biotechnology, Nanotechnology, Research, Health, Technology, Genetics, Clinical trials, Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Molecular genetics, Bioinformatics, Emerging technologies, Synthetic biology, DNA sequencing, Twist Bioscience, Artificial gene synthesis

Pursuing these with the combined solutions of Miroculus and Twist has the potential to advance scientific progress towards these goals substantially.

Key Points: 
  • Pursuing these with the combined solutions of Miroculus and Twist has the potential to advance scientific progress towards these goals substantially.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Pacific Biosciences to Support Sequencing of California Species for the Earth BioGenome Project

Retrieved on: 
Tuesday, February 25, 2020
Branches of biology, Biology, Genetics, Molecular biology, Genomics, Pacific Biosciences, DNA, Genetic mapping, Bioinformatics, Earth BioGenome Project, Genome, Read

MENLO PARK, Calif. and DAVIS, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- The Earth BioGenome Project (EBP) and Pacific Biosciences of California, Inc.(Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that PacBio will support the sequencing of ecologically important organisms in the state of California through the EBP.

Key Points: 
  • MENLO PARK, Calif. and DAVIS, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- The Earth BioGenome Project (EBP) and Pacific Biosciences of California, Inc.(Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that PacBio will support the sequencing of ecologically important organisms in the state of California through the EBP.
  • Currently, fewer than 4,500 or about 0.3 per cent of all known eukaryotic species have had their genome sequenced, with approximately 100 at reference quality.
  • For more information please visit www.earthbiogenome.org/
    Pacific Biosciences of California, Inc.(NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems.
  • Pacific Biosciences technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes.

Adverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer

Retrieved on: 
Tuesday, February 25, 2020
Branches of biology, Biology, Life sciences, Spinal muscular atrophy, Emerging technologies, Gene delivery, Medical genetics, Molecular biology, AveXis, Adverum Biotechnologies, Novartis, Gene therapy

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Angela Thedinga has been promoted to chief technology officer.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Angela Thedinga has been promoted to chief technology officer.
  • I am pleased to congratulate Angela on her role as CTO, who since joining the company has demonstrated executive leadership across the organization and strategic insight, said Leone Patterson, president and chief executive officer of Adverum Biotechnologies.
  • Before joining Adverum, Ms. Thedinga served as vice president of program management and chief of staff at AveXis, Inc., a gene therapy company acquired by Novartis in 2018.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.

Global Protein Sequencing Market Drivers, Restraints & Opportunities During the Forecast Period, 2019-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 25, 2020
Health, General Health, Branches of biology, Molecular biology, Biology, Biochemistry, Biotechnology, Sequencing, DNA

The "Protein Sequencing Market by Product and Service Technology and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Protein Sequencing Market by Product and Service Technology and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global protein sequencing market size was valued at $ 5,399.9 million in 2018 and is expected to reach $ 9,926.7 million by 2026, registering a CAGR of 7.8% from 2019 to 2026.
  • The protein sequencing market share and analysis is based on a comprehensive analysis of key developments in the industry.
  • The quantitative analysis of the global protein sequencing market from 2019 to 2026 is provided to determine the market potential.

Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA

Retrieved on: 
Tuesday, February 25, 2020
Health, FDA, Genetics, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Food and Drug Administration, Emerging technologies, Gene delivery, Medical genetics, Molecular biology, Gene therapy, Fast track, Priority review, MPS IIIA, LYS-SAF302, Lysogene

Lysogene (Paris:LYS) (FR0013233475 LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its LYS-SAF302 program for the treatment of mucopolysaccharidosis Type IIIA (MPS IIIA).

Key Points: 
  • Lysogene (Paris:LYS) (FR0013233475 LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its LYS-SAF302 program for the treatment of mucopolysaccharidosis Type IIIA (MPS IIIA).
  • A product that receives Fast Track designation is eligible for more frequent interactions with FDA, potential eligibility for accelerated approval, priority review, and rolling Biologics License Application (BLA) review.
  • This Fast Track designation demonstrates the regulators sustained interest in Lysogenes cutting edge in vivo gene therapy program.
  • LYS-SAF302 is an AAV-mediated gene therapy, the goal of which is to replace the faulty SGSH gene with a healthy copy of the gene.

The Global PCR System for Food Diagnostics Market is expected to grow by USD 833.14 mn during 2020-2024, progressing at a CAGR of 8% during the forecast period

Retrieved on: 
Monday, February 24, 2020
Natural sciences, Molecular biology, Polymerase chain reaction, Laboratory techniques, Branches of biology, Physical sciences, Biotechnology, Amplifiers, Marketplace

This study identifies advances in pcr system as the prime reasons driving the global pcr system for food diagnostics market growth during the next few years.

Key Points: 
  • This study identifies advances in pcr system as the prime reasons driving the global pcr system for food diagnostics market growth during the next few years.
  • The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Dovetail Genomics Introduces New Dovetail™ Micro-C and HiChIP Kits

Retrieved on: 
Monday, February 24, 2020
Branches of biology, Biology, Nuclear organization, Epigenetics, Molecular biology, Protein methods, Chromatin, Nucleosome, Chromosome conformation capture, Dovetail joint

SCOTTS VALLEY, Calif., Feb. 24, 2020 /PRNewswire/ --Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, today announced the global availability of its latest offerings, Dovetail Micro-C and HiChIP Kits.

Key Points: 
  • SCOTTS VALLEY, Calif., Feb. 24, 2020 /PRNewswire/ --Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, today announced the global availability of its latest offerings, Dovetail Micro-C and HiChIP Kits.
  • Dovetail Micro-C is the latest in an expanding suite of Dovetail Hi-C products and offers researchers superior resolution of chromatin contacts down to the mono-nucleosome level.
  • As a result, the new Dovetail Micro-C and HiChIP Kits present powerful new tools for ultra-high-resolution exploration of chromatin topology, the mechanisms for chromatin compaction, and the relationship between chromatin state and gene expression.
  • Dovetail Genomics LLC is transforming genomics by making long-range information readily accessible to all.

Twist Bioscience Launches New NGS Solutions, Highlights Customers at 2020 Advances in Genome Biology and Technology Conference

Retrieved on: 
Monday, February 24, 2020
Software, Research, Pharmaceutical, Oncology, Data management, Technology, Semiconductor, Genetics, Science, Nanotechnology, Biotechnology, Health, Branches of biology, Biotechnology, Life sciences, Helices, Molecular biology, DNA, Systems biology, Synthetic biology, DNA supercoil, Biology, the Twist NGS Target Enrichment Solutions, Twist Bioscience Corporation

Twist is highlighting these new solutions as well as customer testimonials at the 2020 Advances in Genome Biology and Technology (AGBT) meeting, held from February 23, 2020 to February 26, 2020, in Florida.

Key Points: 
  • Twist is highlighting these new solutions as well as customer testimonials at the 2020 Advances in Genome Biology and Technology (AGBT) meeting, held from February 23, 2020 to February 26, 2020, in Florida.
  • During the meeting, several customers will demonstrate their use of Twists NGS target enrichment solutions for numerous clinical research applications.
  • Building on these important use cases, we are committed to continue to deliver DNA-based products that interrogate biology and enable improved clinical outcomes.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

Magenta Conditioning Lead Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates

Retrieved on: 
Monday, February 24, 2020
Biotechnology, Genetics, Health, Oncology, Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Emerging technologies, Gene therapy, Molecular biology, Hematopoietic stem cell transplantation, Therapy, Organ transplantation

There is a significant opportunity to allow more patients to benefit from immune reset through stem cell transplant with novel, targeted medicines for conditioning.

Key Points: 
  • There is a significant opportunity to allow more patients to benefit from immune reset through stem cell transplant with novel, targeted medicines for conditioning.
  • We are excited to present the first results from our MGTA-117 clinical candidate for targeted patient preparation for stem cell transplant or gene therapy.
  • These new data highlight the potency, safety and broad pre-clinical therapeutic index of 30 fold of MGTA-117.
  • The Company intends to move this new product candidate into the clinic with initial clinical data in 2021.